M. R. Grever, J. S. Blachly, and L. A. Andritsos, Hairy cell leukemia: update on molecular profiling and therapeutic advances, Blood Rev, vol.28, pp.197-203, 2014.

J. D. Rosenberg, C. Burian, J. Waalen, and A. Saven, Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series, Blood, vol.123, pp.177-83, 2014.

R. J. Kreitman, Immunoconjugates and new molecular targets in hairy cell leukemia, Hematol Am Soc Hematol Educ Program, vol.2012, pp.660-666, 2012.

P. A. Thompson and F. Ravandi, How I manage patients with hairy cell leukaemia, Br J Haematol, vol.177, pp.543-56, 2017.

M. Else, C. E. Dearden, E. Matutes, J. Garcia-talavera, A. Z. Rohatiner et al., Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis, Br J Haematol, vol.145, pp.733-773, 2009.

B. M. Getta, J. H. Park, and M. S. Tallman, Hairy cell leukemia: past, present and future, Best Pract Res Clin Haematol, vol.28, pp.269-72, 2015.

P. L. Zinzani, C. Pellegrini, V. Stefoni, E. Derenzini, L. Gandolfi et al., Hairy cell leukemia: evaluation of the long-term outcome in 121 patients, Cancer, vol.116, pp.4788-92, 2010.

M. R. Grever, O. Abdel-wahab, L. A. Andritsos, V. Banerji, J. Barrientos et al., Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia, Blood, vol.129, pp.553-60, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02194198

E. Tiacci, J. H. Park, D. Carolis, L. Chung, S. S. Broccoli et al., Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia, N Engl J Med, vol.373, pp.1733-1780, 2015.

H. Hagberg and L. Lundholm, Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia, Br J Haematol, vol.115, pp.609-620, 2001.

F. Lauria, M. Lenoci, L. Annino, D. Raspadori, G. Marotta et al., Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia, Haematologica, vol.86, pp.1046-50, 2001.

J. Nieva, K. Bethel, and A. Saven, Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia, Blood, vol.102, pp.810-813, 2003.

D. A. Thomas, S. O'brien, C. Bueso-ramos, S. Faderl, M. J. Keating et al., Rituximab in relapsed or refractory hairy cell leukemia, Blood, vol.102, pp.3906-3917, 2003.

M. K. Angelopoulou, G. A. Pangalis, S. Sachanas, S. I. Kokoris, K. Anargyrou et al., Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. Leuk Lymphoma, vol.49, pp.1817-1837, 2008.

F. Ravandi, J. L. Jorgensen, S. M. O'brien, S. Verstovsek, C. A. Koller et al., Eradication of minimal residual disease in hairy cell leukemia, Blood, vol.107, pp.4658-62, 2006.

F. Ravandi, S. O'brien, J. Jorgensen, S. Pierce, S. Faderl et al., Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia, Blood, vol.118, pp.3818-3841, 2011.

M. Burotto, M. Stetler-stevenson, E. Arons, H. Zhou, W. Wilson et al., Bendamustine and rituximab in relapsed and refractory hairy cell leukemia, Clin Cancer Res, vol.19, pp.6313-6334, 2013.

J. Jones, L. Andritsos, R. J. Kreitman, F. Ravandi, C. Schiffer et al., Efficacy and safety of the bruton tyrosine kinase inhibitor ibrutinib in patients with hairy cell leukemia: stage 1 results of a phase 2 study, Blood, vol.128, p.1215, 2016.

R. J. Kreitman and I. Pastan, Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox, Clin Cancer Res, vol.17, pp.6398-405, 2011.

R. J. Kreitman, M. S. Tallman, T. Robak, S. Coutre, W. H. Wilson et al., Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up, Blood, vol.131, issue.21, pp.2331-2335, 2018.

J. R. Kreitman, C. Dearden, P. Zinzani, J. Delgado, L. Karlin et al., Moxetumomab pasudotox induces high rates of durable complete response and eradication of minimal residual disease in heavily pretreated patients with relapsed/refractory hairy cell leukemia: results of a pivotal international study (abstract), p.59

, Annual Meeting of the American Society of Hematology, 2017.

G. A. Atlanta,

V. Divino, S. Karve, A. Gaughan, M. Dekoven, G. Gao et al., Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis, J Comp Eff Res, vol.6, pp.497-508, 2017.

M. S. Tallman, Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping, Leuk Lymphoma, vol.52, issue.2, pp.65-73, 2011.

P. Mhawech-fauceglia, M. Oberholzer, S. Aschenafi, A. Baur, M. Kurrer et al., Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia, Arch Pathol Lab Med, vol.130, pp.374-381, 2006.

R. J. Kreitman, M. S. Tallman, T. Robak, S. Coutre, W. H. Wilson et al., Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patient with hairy cell leukemia, J Clin Oncol, vol.30, pp.1822-1830, 2012.

R. J. Kreitman, M. Stetler-stevenson, I. Margulies, P. Noel, D. J. Fitzgerald et al., Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia, J Clin Oncol, vol.27, pp.2983-90, 2009.

R. J. Kreitman, W. H. Wilson, K. Bergeron, M. Raggio, M. Stetlerstevenson et al., Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairycell leukemia, N Engl J Med, vol.345, pp.241-248, 2001.